Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D R Budman

Showing results (81-90 of 110) with videos related to

Pageof 11
Sort By:
Cancer Research|December 1, 1985
Pharmacokinetics of low-dose 1-beta-D-arabinofuranosylcytosine given by continuous intravenous infusion over twenty-one daysW Kreis, F Chaudhri, K Chan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1996
Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541G L Rosner, J B Hargis, D R Hollis, et al.
Diseases of the Colon and Rectum|December 1, 1994
Prospective analysis of colorectal carcinoma. Determination of an age-site and stage relationship and the correlation of DNA index with clinicopathologic parametersS M Lichtman, F Mandel, B Hoexter, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Pharmacokinetic evaluation of zeniplatin in humansL C DeMarco, D R Budman, C Lathia, et al.
Leukemia & Lymphoma|July 27, 2016
Phase II Trial of Fludarabine Phosphate in Multiple Myeloma Using a Loading Dose and Continuous Infusion ScheduleS M Lichtman, A Mittelman, D R Budman, et al.
Leukemia|November 1, 1991
Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot studyW Kreis, D R Budman, K Chan, et al.
American Journal of Hematology|March 1, 1995
Morphological, ultrastructural, and genetic characterization of an unusual T-cell lymphoma in a patient with sinus histiocytosis with massive lymphadenopathyP R Koduru, M Susin, J E Kolitz, et al.
Journal of the American Geriatrics Society|April 1, 1996
No increased risk of Taxol toxicity in older patientsS M Lichtman, W Zaheer, D Gal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1994
Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumorsD R Budman, L N Igwemezie, S Kaul, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatinJ H Marsh, W Kreis, B Barile, et al.
Pageof 11

Showing results (81-90 of 110) with videos related to

Sort By:
Pageof 11
Cancer Research|December 1, 1985
Pharmacokinetics of low-dose 1-beta-D-arabinofuranosylcytosine given by continuous intravenous infusion over twenty-one daysW Kreis, F Chaudhri, K Chan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1996
Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541G L Rosner, J B Hargis, D R Hollis, et al.
Diseases of the Colon and Rectum|December 1, 1994
Prospective analysis of colorectal carcinoma. Determination of an age-site and stage relationship and the correlation of DNA index with clinicopathologic parametersS M Lichtman, F Mandel, B Hoexter, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Pharmacokinetic evaluation of zeniplatin in humansL C DeMarco, D R Budman, C Lathia, et al.
Leukemia & Lymphoma|July 27, 2016
Phase II Trial of Fludarabine Phosphate in Multiple Myeloma Using a Loading Dose and Continuous Infusion ScheduleS M Lichtman, A Mittelman, D R Budman, et al.
Leukemia|November 1, 1991
Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot studyW Kreis, D R Budman, K Chan, et al.
American Journal of Hematology|March 1, 1995
Morphological, ultrastructural, and genetic characterization of an unusual T-cell lymphoma in a patient with sinus histiocytosis with massive lymphadenopathyP R Koduru, M Susin, J E Kolitz, et al.
Journal of the American Geriatrics Society|April 1, 1996
No increased risk of Taxol toxicity in older patientsS M Lichtman, W Zaheer, D Gal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1994
Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumorsD R Budman, L N Igwemezie, S Kaul, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatinJ H Marsh, W Kreis, B Barile, et al.
Pageof 11